Combination Chemotherapy With or Without Valspodar in Treating Patients With Previously Untreated Acute Myeloid Leukemia
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Randomized phase III trial to compare the effectiveness of combination chemotherapy with or
without PSC 833 followed by interleukin-2 or no further therapy in treating older patients
who have acute myeloid leukemia. Some cancers become resistant to chemotherapy drugs.
Combining PSC 833 with more than one chemotherapy drug may reduce resistance to the drugs and
allow the cancer cells to be killed. Combining interleukin-2 with combination chemotherapy
plus PSC 833 may kill more cancer cells.